A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent lub jego opiekun prawny musi podpisać zgodę na udział w badaniu
- •Pacjent otrzymuje lek tislelizumab jako część standardowego leczenia, zgodnie z decyzją swojego lekarza
✗ Disqualifies
- •Pacjent nie rozumie warunków i konsekwencji udziału w badaniu
- •Pacjent ma przeciwwskazania do stosowania leku tislelizumab według opinii lekarza prowadzącego
- •Pacjent nie spełnia kryteriów kwalifikacji do badania według lekarza prowadzącego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
Hospital Universitario Reina Sofía
Córdoba, Spain
Hospital Universitario de Jaén
Jaén, Spain
Hospital Universitario Lucus Augusti (HULA)
Lugo, Spain
Hospital de Segovia
Segovia, Spain
Hospital General de Segovia
Segovia, Spain
Hospital de Sagunto
Valencia, Spain
Trial contact
Study Director
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/16/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.